GIP / GLP-1 dual receptor agonist
Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist with FDA-approved uses and a large human evidence base. Its approved brands have different labeled indications, while several additional research areas remain investigational.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
Large Phase 3 and outcomes trials span diabetes, weight, sleep apnoea, heart failure, liver disease, and cardiovascular risk.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Multiple large randomized trials and current product labels support defined uses; unstudied populations and very long-term durability remain separate questions.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Trial arms and product-label schedules answer different questions. Neither is a personalized recommendation, and tirzepatide products are not interchangeable with other incretin compounds. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
What the evidence says
Multiple large randomized Phase 3 trials support glycaemic, weight, obstructive-sleep-apnoea, and HFpEF outcomes in defined populations. A 13,299-participant cardiovascular outcomes trial found tirzepatide noninferior—not superior—to dulaglutide for major cardiovascular events.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Individual durability and tolerability over many years, rare-event characterization at population scale, and whether findings extend to unstudied populations or conditions.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
At week 112, mean weight change from the original baseline was −21.9% with continued maximum tolerated tirzepatide, −16.6% after reduction to 5 mg, and −9.9% after switching to placebo.
The primary cardiovascular outcome occurred in 12.2% with tirzepatide and 13.1% with dulaglutide (hazard ratio 0.92). Tirzepatide met noninferiority, but not superiority.
Least-squares mean weight change was −20.2% with tirzepatide and −13.7% with semaglutide; waist change was −18.4 cm versus −13.0 cm.
Cardiovascular death or a worsening heart-failure event occurred in 9.9% with tirzepatide and 15.3% with placebo (hazard ratio 0.62). At week 52, the between-group difference in KCCQ-CSS change was 6.9 points.
At week 176, mean weight change was −12.3%, −18.7%, and −19.7% with tirzepatide versus −1.3% with placebo. Diabetes developed in 1.3% of pooled tirzepatide participants versus 13.3% with placebo during treatment.
Administration and handling
Current U.S. labels describe once-weekly subcutaneous use. Zepbound starts at 2.5 mg weekly for 4 weeks, then 5 mg, with 2.5 mg increases only after at least 4 weeks; labeled maintenance depends on indication and the maximum is 15 mg weekly. Mounjaro uses the same adult escalation framework. This is a summary of official labeling—not a personalized recommendation.
FDA-approved Mounjaro and Zepbound presentations are clear solutions and do not require reconstitution. Labels say to protect them from heat and light and not freeze them. Exact refrigerated and room-temperature limits differ by presentation, so the current product label and packaging—not generic online instructions—are the controlling source.
Primary-source ledger
2026-05-12 · PMID 42119587 · NCT06047548 · DOI 10.1016/S0140-6736(26)00656-2
2026-02-01
2026-01-01
2025-12-17 · PMID 41406444 · NCT04255433 · DOI 10.1056/NEJMoa2505928
2025-05-11 · PMID 40353578 · NCT05822830 · DOI 10.1056/NEJMoa2416394
2024-11-16 · PMID 39555826 · NCT04847557 · DOI 10.1056/NEJMoa2410027
2024-11-13 · PMID 39536238 · NCT04184622 · DOI 10.1056/NEJMoa2410819
2024-06-21 · PMID 38912654 · NCT05412004 · DOI 10.1056/NEJMoa2404881
2024-06-08 · PMID 38856224 · NCT04166773 · DOI 10.1056/NEJMoa2401943
2023-12-11 · PMID 38078870 · NCT04660643 · DOI 10.1001/jama.2023.24945
2023-06-26 · PMID 37385275 · NCT04657003 · DOI 10.1016/S0140-6736(23)01200-X
2022-06-04 · PMID 35658024 · NCT04184622 · DOI 10.1056/NEJMoa2206038
2021-06-25 · PMID 34170647 · NCT03987919 · DOI 10.1056/NEJMoa2107519